Clinical Trials Logo

Neoplasms, Unknown Primary clinical trials

View clinical trials related to Neoplasms, Unknown Primary.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04276597 Withdrawn - Clinical trials for Neuroendocrine Tumors

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

PUTNET
Start date: March 4, 2020
Phase: Phase 2
Study type: Interventional

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET. The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.

NCT ID: NCT00458315 Withdrawn - Clinical trials for Unknown Primary Tumors

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Start date: May 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy of Cisplatin, Paclitaxel, Gemcitabine +/- Avastin (Bevacizumab) in patients with unknown primary tumors.

NCT ID: NCT00119314 Withdrawn - Clinical trials for Carcinoma of Unknown Primary

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Start date: July 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with docetaxel and capecitabine works in treating patients with cancer of unknown primary origin.